Sentiment Trading

MoonLake Immunotherapeutics reported strong Q1 2025 results, with significant progress in its flagship sonelokimab’s clinical trials for inflammatory conditions, positioning the company for potential growth in the chronic pruritus market.

MoonLake Immunotherapeutics reported strong Q1 2025 financial results, with $480.1 million in cash, and made significant progress in the development of its lead investigational therapy, sonelokimab, for inflammatory diseases.